US20220020286A1 - Optimized effectiveness based sleep aid management - Google Patents
Optimized effectiveness based sleep aid management Download PDFInfo
- Publication number
- US20220020286A1 US20220020286A1 US17/132,424 US202017132424A US2022020286A1 US 20220020286 A1 US20220020286 A1 US 20220020286A1 US 202017132424 A US202017132424 A US 202017132424A US 2022020286 A1 US2022020286 A1 US 2022020286A1
- Authority
- US
- United States
- Prior art keywords
- user
- melatonin
- sleep
- machine learning
- learning model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 115
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 87
- 229960003987 melatonin Drugs 0.000 claims abstract description 87
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 87
- 230000006399 behavior Effects 0.000 claims abstract description 42
- 238000010801 machine learning Methods 0.000 claims abstract description 39
- 238000005457 optimization Methods 0.000 claims abstract description 21
- 238000012544 monitoring process Methods 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 6
- 229940088597 hormone Drugs 0.000 claims abstract description 5
- 239000005556 hormone Substances 0.000 claims abstract description 5
- 230000035945 sensitivity Effects 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 15
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 12
- 238000011160 research Methods 0.000 claims description 12
- 238000012549 training Methods 0.000 claims description 12
- 238000011156 evaluation Methods 0.000 claims description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960001948 caffeine Drugs 0.000 claims description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 3
- 235000012631 food intake Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 description 35
- 230000008569 process Effects 0.000 description 13
- 230000003542 behavioural effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000036626 alertness Effects 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 230000003284 homeostatic effect Effects 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022035 Initial insomnia Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000036757 core body temperature Effects 0.000 description 2
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0806—Detecting, measuring or recording devices for evaluating the respiratory organs by whole-body plethysmography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4815—Sleep quality
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4818—Sleep apnoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/486—Bio-feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
- A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/02—Knowledge representation; Symbolic representation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
- A61B2560/0247—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value
- A61B2560/0257—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value using atmospheric pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1118—Determining activity level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Definitions
- the disclosed concept pertains to methods and systems for effectively administering sleep aids, and, in particular, to methods and systems for optimizing sleep through the administration of exogenous melatonin.
- exogenous melatonin has become one of the most frequently requested non-prescription sleep aids due to its regulator role in the internal timing of biological rhythms, including promotion/regulation of sleep.
- Melatonin is marketed to help promote total sleep time, aid with fatigue from jet lag, or balance circadian rhythms from jet lag and rotating shift work.
- Evidence suggests melatonin may reduce the time it takes for people with delayed sleep phase syndrome to fall asleep as well as to help reset the body's sleep-wake cycle.
- Melatonin is secreted during the hours of darkness and is low during daylight hours. As such, exogenous melatonin use is affected by light exposure in addition to other user factors and behavior including age, stress, physical activity, diet, and influence of other hormones. Melatonin in a range of doses (0.5-6 mg) in different formulations (fast and slow release) given at different times before bedtime (0.5-2 h) has been shown in some studies to improve some subjective and objective sleep parameters, as measured by actigraphy or polysomnography, but conflicting data exist. In literature reviews of melatonin effectiveness, general findings of studies with exclusively healthy volunteers make weak recommendations in favor of melatonin use for initiating sleep or sleep efficiency and daytime sleepiness or somnolence.
- a melatonin optimization system for optimizing the effectiveness of exogenous melatonin in achieving a desired sleep outcome for a user
- the system including: a user interface configured to accept information input to the user interface regarding health conditions, self-reported behavior, and a desired sleep outcome of the user; a sleep architecture detection module configured to perform monitoring of a sleep architecture of the user and to detect a hormone sensitivity of the user through the monitoring; a behavior detection module configured to detect and collect information about behavior of the user in order to define a detected behavior of the user; an initial dose algorithm module configured to define an initial advised dose of melatonin for the user; an effectiveness evaluation module configured to determine an outcome difference between the desired sleep outcome of the user and a measured sleep outcome of the user; and a recommendation engine configured to define an intervention for the user to reduce the outcome difference.
- the initial dose algorithm module is configured to define the initial advised dose of melatonin based on the information input to the user interface, and the recommendation engine is configured to define the intervention based on the outcome difference, the monitoring of the sleep architecture, the detected behavior of the user, and the initial advised dose of melatonin.
- FIG. 1 shows a schematic depiction of a melatonin optimization system, according to an exemplary embodiment of the disclosed concept
- FIG. 2 shows a schematic depiction of a more detailed variation of the melatonin optimization system depicted in FIG. 1 , according to an exemplary embodiment of the disclosed concept;
- FIG. 3 shows a graph illustrating a two-process model of sleep alertness
- FIG. 4 is a schematic depiction of a multi-modal input sleep onset latency prediction module that can be included in an effectiveness evaluation module of either of the systems depicted in FIG. 1 and FIG. 2 , according to an exemplary embodiment of the disclosed concept;
- FIG. 5 is a flow chart containing the steps of a method for training a machine learning model to predict sleep onset latency for a user of either of the systems depicted in FIG. 1 and FIG. 2 , according to an exemplary embodiment of the disclosed concept.
- number shall mean one or an integer greater than one (i.e., a plurality).
- controller shall mean a number of programmable analog and/or digital devices (including an associated memory part or portion) that can store, retrieve, execute and process data (e.g., software routines and/or information used by such routines), including, without limitation, a field programmable gate array (FPGA), a complex programmable logic device (CPLD), a programmable system on a chip (PSOC), an application specific integrated circuit (ASIC), a microprocessor, a microcontroller, a programmable logic controller, or any other suitable processing device or apparatus.
- FPGA field programmable gate array
- CPLD complex programmable logic device
- PSOC programmable system on a chip
- ASIC application specific integrated circuit
- the memory portion can be any one or more of a variety of types of internal and/or external storage media such as, without limitation, RAM, ROM, EPROM(s), EEPROM(s), FLASH, and the like that provide a storage register, i.e., a non-transitory machine readable medium, for data and program code storage such as in the fashion of an internal storage area of a computer, and can be volatile memory or nonvolatile memory.
- intervention shall refer to a dosage of exogenous melatonin and/or a set of behaviors recommended for a person seeking to change a number of characteristics of his or her sleep.
- machine learning model shall mean a software system that develops and builds a mathematical model based on sample data, known as “training data”, in order to make predictions or decisions without being explicitly programmed to do so, including, without limitation, a computer software system that develops that has been trained to recognize patterns from a set of training data, and subsequently develops algorithms to recognize patterns from the training data set in other data sets.
- exogenous melatonin is administered to effect a timing function of sleep rather than a hypnotic effect; that is, exogenous melatonin is administered to influence when a person falls asleep but may not affect the total amount of time that a person sleeps.
- research literature shows that responses to melatonin administered exogenously (i.e. ingested) are greatest when at times when endogenous levels (i.e. natural bodily production levels) are not normally present, that is, during the day.
- melatonin causes phase delays (shifts to a later time) in the body's biological night as defined by the body's circadian rhythm, and when ingested in the afternoon or evening, exogenous melatonin causes phase advances (shifts to an earlier time) in the body's biological night as defined by the body's circadian rhythm.
- the conditions during which melatonin is administered appear to be very important and may dictate the effectiveness of any given dose, particularly with respect to acute changes in core body temperature (CBT) and sleepiness. Accordingly, the disclosed concept provides a system for optimizing the effectiveness of melatonin treatment by detecting hormone sensitivity through sleep architecture monitoring and personalizing dosing in relation to users' behaviors, needs and health conditions.
- dose encompass both the quantity of melatonin to be taken and the timing of ingestion of the melatonin relative to a desired sleep event or time of day.
- FIG. 1 is a schematic depiction of a melatonin optimization system 10 for maximizing melatonin effectiveness based on a user's needs, characteristics, and behavior, in accordance with an exemplary embodiment of the disclosed concept
- FIG. 2 is a schematic depiction of a system 100 that is a more detailed variation of the system 10 .
- FIG. 2 also depicts some of the decision making executed by the components of systems 10 and 100 .
- a behavior detection module 15 is depicted as being separate from a recommendation engine 16 in FIG. 1 while being depicted as part of the recommendation engine 16 in FIG. 2 , and that either configuration can be used without departing from the scope of the disclosed concept.
- the system 10 , 100 collects information about a user's behavior, characteristics, sleep architecture, and desired sleep outcomes as inputs to the system, then analyzes the inputs to make recommendations to help the user achieve the desired sleep outcomes.
- the data collection and analysis tasks of the systems 10 , 100 can be executed by any type of controller or computing system with input/output, processing, and memory capabilities, and any number or combination of such controller or computing systems can be used without departing from the scope of the disclosed concept.
- a user interface 11 allows the user to provide information about his or her age, gender, usual bed time, timing and dosage of caffeine and alcohol intake, health conditions (e.g. high blood pressure, insomnia, diabetes, beta-blocker intake, jet-lag), and desired sleep outcome(s) (i.e. sleep onset latency, sleep/wake time, sleep duration, etc.) to the system 10 , 100 .
- Such user interface 11 can, for example and without limitation, take the form of a mobile phone application or internet-based portal.
- An initial dose algorithm module 12 provides initial melatonin dose and timing recommendations for the user based on the age/gender/conditions/needs/desired sleep time data entered by the user into the user interface 11 .
- the initial dose algorithm module 12 can, for example and without limitation, be preprogrammed to utilize widely available data about recommended dosing based on problems recognized in the general population.
- Table 1 below provides a non-limiting example of widely available data providing a number of melatonin dosages that are recommended based on a user's specific conditions, needs, desired sleep outcomes, etc.:
- a sleep architecture detection module 13 includes a number of sensors and/or trackers and a number of algorithms for detecting the user's sleep architecture. Any type of sensor, tracker, or other device/method for collecting sleep architecture can be used without departing from the disclosed concept. Non-limiting examples of devices that can be used to detect sleep architecture include wrist worn devices, mattresses with sleep trackers, and user-entered sleep diaries.
- An effectiveness evaluation module 14 compares the user's desired sleep outcome (as indicated by the user's input to user interface 11 ) to the actual sleep outcome (as detected by the sleep architecture detection module 13 ), and a recommendation engine 16 (described in more detail below) then directs the user to either change the dosage/timing of the melatonin intake or execute a different intervention for changing a behavioral aspect based on the findings of the effectiveness evaluation module 14 .
- a behavior detection module 15 collects and processes sensor data and the user's self-reported information (input to the user interface 11 ) to detect information about the user's behavior, including but not limited to the user's exposure to light, physical activity, food intake, and stress level.
- the behavior detection module 15 includes, at a minimum: a wearable sensor for light exposure detection, a stress detector, an activity tracker, and an input from the user interface 11 for self-reporting of food/alcohol/caffeine intake.
- the wearable sensor for light exposure detection can, for example and without limitation, detect and collect information about the duration, intensity and timing of both sun and artificial light to which a user is exposed throughout the day and up to the user's bed time.
- the stress detector can, for example and without limitation, be a wearable device that detects user physiological data such as heart rate variability and/or skin conductance.
- the assessment of stress level can be performed either by an on-device algorithm or by a third party via an application programming interface (API) call from the stress detector.
- the activity tracker can, for example and without limitation, be a wearable device that detects the number of minutes that the user is engaged in an aerobic activity, with aerobic activity being characterized by the user's heart rate level reaching between 55% and 85% of the user's maximum heart rate, the maximum heart rate (maxHR) being calculated using Equation (1) below:
- the user interface for self-reporting of food/alcohol/caffeine intake enables a user to report the amount and timing of his or her food, alcohol, and/or caffeine intake throughout the day.
- the recommendation engine 16 comprises a melatonin dose adjustment module 17 and a behavioral changes module 18 that evaluates the melatonin dose effectiveness and analyzes the detected user behavior along with the user's stated preferences to recommend melatonin dosing adjustments and/or behavioral changes for the user. More specifically, the dose adjustment module 17 determines the difference between the user's desired sleep onset latency and measured sleep onset latency (or any other chosen sleep metric), and recommends an intervention based on the effectiveness of any previous melatonin intervention, the current day's activities, and the prior night's sleep. If the recommended intervention is melatonin dosing and the previous melatonin dose already reached a predetermined maximum allowed level, then only behavioral changes will be recommended. The behavioral changes module 18 computes the difference between recommended behavior for the user and the user's measured behavior. If the behavior difference exceeds a pre-defined threshold, then an intervention is recommended.
- behavioral change recommendations are provided only for the actual behaviors that are being monitored. For example and without limitation, if the particular implementation of a system 10 being used does not include a light sensor, then the behavioral changes module 18 will not provide light exposure recommendations.
- a non-limiting list of behavioral change recommendations that can be provided by the behavioral changes module 18 includes: directing the user to engage in an outdoor activity such as walking for at least 30 minutes a day, directing the user to turn off artificial lights at least two hours before the desired time of sleep onset, directing the user to engage in breathing exercises to assist in reducing the user's stress level, and directing the user to avoid caffeine intake after a specified time of day.
- the effectiveness module 14 can additionally predict non-intervention sleep onset (i.e. naturally occurring sleep onset) using a number of statistical or empirical techniques, and use the predicted non-intervention sleep onset as part of the evaluation of the effectiveness of any current intervention.
- the predicted non-intervention sleep onset can then be used by the recommendation engine 16 to determine a recommended intervention for the upcoming night (or other period of sleep).
- a technique that the effectiveness module 14 can employ for predicting sleep onset is a two-process model of sleep alertness.
- the two-process model of sleep alertness uses time since awakening, time since falling asleep, and time of day to generate a sleep-dependent curve (Process S) and sleep-independent circadian curve (Process C).
- the Process S curve demonstrates that alertness is highest upon waking and decreases steadily throughout the day, reaching its lowest level at sleep onset (represented by the lowest value on the Process S curve).
- the Process S reverses at sleep onset and is called S′ until awakening.
- the S′ portion of the Process S curve shows that homeostatic sleep debt is relieved during sleep.
- a predicted alertness level for the time of day is expressed as the arithmetic sum of the S and C curves (depicted as a dashed line S+C in FIG. 3 ).
- Sleep onset latency (SOL) for any given time of day can then be predicted using Equation (2) below:
- Equation (2) x is the predicted alertness for a specified time of day (i.e. found by locating the S+C curve point corresponding to the time of day) and y is the sleep onset latency.
- x is the predicted alertness for a specified time of day (i.e. found by locating the S+C curve point corresponding to the time of day)
- y is the sleep onset latency.
- the effectiveness module 14 can include a SOL prediction module 140 incorporating a machine learning model 145 (the SOL prediction module 140 and machine learning model 145 both being described in more detail with respect to FIGS. 4 and 5 ) to predict sleep onset latency n hours before the user's desired bedtime.
- the user's preferred bedtime can either be expressed by the user through the user interface 11 or can be automatically detected from historical sleep architecture data collected by the sleep architecture detection module 13 , by averaging bedtime detected over a week of use, and averaging bedtime separately over weekdays and weekends if different sleep routines are present in those two parts of the week.
- the machine learning model 145 can be configured to implement a personalized SOL prediction tailored to a particular user of the system 10 , 100 .
- the machine learning model 145 can be trained to make user-personalized SOL predictions by analyzing sleep architecture data collected by the sleep architecture detection module 13 .
- the accuracy of a personalized SOL prediction function that allows for multiple inputs can be maximized by minimizing the value of an error function defined in Equation (3) below:
- a new user is first directed at step 201 of the method 200 to use the system 10 or system 100 for a baseline period (e.g. one week) without taking any melatonin.
- the user is directed at step 202 to take varying doses of melatonin throughout the course of a subsequent testing period (e.g. one week), wherein the doses are defined as either minimum, maximum, or intermediate (e.g. the intermediate dose being defined as halfway between the maximum dose and minimum dose).
- the baseline period and the testing period comprise a data collection period.
- the durations of the baseline period and the testing period can be longer or shorter than one week, and that the durations of the baseline period and the testing period can vary from one another without departing from the scope of the disclosed concept.
- the testing period or baseline period for the user can also be omitted entirely without departing from the disclosed concept such that the machine learning model 145 can be trained using comparable available data from dedicated research trials wherein sleep architecture data was collected for multiple research subjects who underwent a baseline period and a testing period; however, it will be appreciated that the SOL prediction made by the machine learning model 145 in that instance would not be personalized for the user of the system 10 or 100 .
- the SOL prediction module 140 is depicted as including a two-process (2-P) SOL prediction module.
- the 2-P SOL prediction module uses an algorithm that takes the two processes of homeostatic sleep drive and circadian timing (i.e. the Process S curve and the Process C curve, respectively, shown in FIG. 3 ) into account in predicting sleep onset latency.
- the Unified Model of Performance, the SAFTE model, or any other biological model that takes into account homeostatic sleep drive and circadian timing can be used in place of the 2-P model in the SOL prediction module 140 without departing from the scope of the disclosed concept. Referring to FIG.
- the machine learning model 145 analyzes the baseline period data, the testing period data, and the behavior detection module 15 data (if applicable) for each day of the data collection period and compares the data to the user's detected sleep architecture collected every day of the data collection period by the sleep architecture detection module 13 in order to determine patterns indicative of SOL.
- user baseline data and testing data may not be provided to the machine learning model 145 at step 205 , and research subject baseline data and testing data are instead provided so that the machine learning model 145 can compare the research subjects' baseline data and testing data to the research subjects' sleep architecture data in order to determine patterns indicative of SOL.
- the machine learning model 145 is capable of making a reliable SOL prediction based on newly provided data about the user's sleep architecture from the previous night (or other sleeping period), the most recent melatonin dose taken by the user, and the user's most recent behavior (if applicable).
- machine learning model 145 used in the SOL prediction module 140 , including but not limited to decision tree regressors, generalized linear models, and other regression modeling task solutions, and that any technique for building a machine learning model may be used to build machine learning model 145 without departing from the scope of the disclosed concept.
- any reference signs placed between parentheses shall not be construed as limiting the claim.
- the word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim.
- several of these means may be embodied by one and the same item of hardware.
- the word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements.
- any device claim enumerating several means several of these means may be embodied by one and the same item of hardware.
- the mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Theoretical Computer Science (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Mathematical Physics (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 63/054,197, filed on 20 Jul. 2020. This application is hereby incorporated by reference herein.
- The disclosed concept pertains to methods and systems for effectively administering sleep aids, and, in particular, to methods and systems for optimizing sleep through the administration of exogenous melatonin.
- In 2016, 27 percent of people in a new Consumer Reports survey of 4,023 U.S. adults said they had trouble falling asleep or staying asleep most nights, and 68 percent—or an estimated 164 million Americans—struggled with sleep at least once a week. Of interest, approximately 5.2% of the 2002 NHIS Alternative Health/Complementary and Alternative Medicine supplement survey respondents reported using melatonin and 27.5% of those users reported insomnia as a reason for taking the supplement, regardless of proven efficacy. As individuals in the United States and beyond look to combat sleep issues, melatonin supplements have garnered a strong over the counter market with a global value of 1 billion USD in 2020.
- Indeed, exogenous melatonin has become one of the most frequently requested non-prescription sleep aids due to its regulator role in the internal timing of biological rhythms, including promotion/regulation of sleep. Melatonin is marketed to help promote total sleep time, aid with fatigue from jet lag, or balance circadian rhythms from jet lag and rotating shift work. Evidence suggests melatonin may reduce the time it takes for people with delayed sleep phase syndrome to fall asleep as well as to help reset the body's sleep-wake cycle.
- Melatonin is secreted during the hours of darkness and is low during daylight hours. As such, exogenous melatonin use is affected by light exposure in addition to other user factors and behavior including age, stress, physical activity, diet, and influence of other hormones. Melatonin in a range of doses (0.5-6 mg) in different formulations (fast and slow release) given at different times before bedtime (0.5-2 h) has been shown in some studies to improve some subjective and objective sleep parameters, as measured by actigraphy or polysomnography, but conflicting data exist. In literature reviews of melatonin effectiveness, general findings of studies with exclusively healthy volunteers make weak recommendations in favor of melatonin use for initiating sleep or sleep efficiency and daytime sleepiness or somnolence. Inconsistent study results can be attributed, in part, to individual-to-individual variation. Despite the large global market and the millions of US adults who report using melatonin, the question of appropriate dose and formulation of melatonin for the adjustment of circadian rhythms and sleep problems has not been resolved. Accordingly, there is room for improvement in methods and systems for determining personally relevant dosing schedules of melatonin.
- Accordingly, it is an object of the present invention to provide, in an exemplary embodiment, a melatonin optimization system for optimizing the effectiveness of exogenous melatonin in achieving a desired sleep outcome for a user, the system including: a user interface configured to accept information input to the user interface regarding health conditions, self-reported behavior, and a desired sleep outcome of the user; a sleep architecture detection module configured to perform monitoring of a sleep architecture of the user and to detect a hormone sensitivity of the user through the monitoring; a behavior detection module configured to detect and collect information about behavior of the user in order to define a detected behavior of the user; an initial dose algorithm module configured to define an initial advised dose of melatonin for the user; an effectiveness evaluation module configured to determine an outcome difference between the desired sleep outcome of the user and a measured sleep outcome of the user; and a recommendation engine configured to define an intervention for the user to reduce the outcome difference. The initial dose algorithm module is configured to define the initial advised dose of melatonin based on the information input to the user interface, and the recommendation engine is configured to define the intervention based on the outcome difference, the monitoring of the sleep architecture, the detected behavior of the user, and the initial advised dose of melatonin.
- These and other objects, features, and characteristics of the present invention, as well as the methods of operation and functions of the related elements of structure and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention.
-
FIG. 1 shows a schematic depiction of a melatonin optimization system, according to an exemplary embodiment of the disclosed concept; -
FIG. 2 shows a schematic depiction of a more detailed variation of the melatonin optimization system depicted inFIG. 1 , according to an exemplary embodiment of the disclosed concept; -
FIG. 3 shows a graph illustrating a two-process model of sleep alertness; -
FIG. 4 is a schematic depiction of a multi-modal input sleep onset latency prediction module that can be included in an effectiveness evaluation module of either of the systems depicted inFIG. 1 andFIG. 2 , according to an exemplary embodiment of the disclosed concept; and -
FIG. 5 is a flow chart containing the steps of a method for training a machine learning model to predict sleep onset latency for a user of either of the systems depicted inFIG. 1 andFIG. 2 , according to an exemplary embodiment of the disclosed concept. - As used herein, the singular form of “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.
- As used herein, the statement that two or more parts or components are “coupled” shall mean that the parts are joined or operate together either directly or indirectly, i.e., through one or more intermediate parts or components, so long as a link occurs.
- As used herein, the term “number” shall mean one or an integer greater than one (i.e., a plurality).
- As used herein, the term “controller” shall mean a number of programmable analog and/or digital devices (including an associated memory part or portion) that can store, retrieve, execute and process data (e.g., software routines and/or information used by such routines), including, without limitation, a field programmable gate array (FPGA), a complex programmable logic device (CPLD), a programmable system on a chip (PSOC), an application specific integrated circuit (ASIC), a microprocessor, a microcontroller, a programmable logic controller, or any other suitable processing device or apparatus. The memory portion can be any one or more of a variety of types of internal and/or external storage media such as, without limitation, RAM, ROM, EPROM(s), EEPROM(s), FLASH, and the like that provide a storage register, i.e., a non-transitory machine readable medium, for data and program code storage such as in the fashion of an internal storage area of a computer, and can be volatile memory or nonvolatile memory.
- As used herein, the term “intervention” shall refer to a dosage of exogenous melatonin and/or a set of behaviors recommended for a person seeking to change a number of characteristics of his or her sleep.
- As used herein, the term “machine learning model” shall mean a software system that develops and builds a mathematical model based on sample data, known as “training data”, in order to make predictions or decisions without being explicitly programmed to do so, including, without limitation, a computer software system that develops that has been trained to recognize patterns from a set of training data, and subsequently develops algorithms to recognize patterns from the training data set in other data sets.
- Directional phrases used herein, such as, for example and without limitation, top, bottom, left, right, upper, lower, front, back, and derivatives thereof, relate to the orientation of the elements shown in the drawings and are not limiting upon the claims unless expressly recited therein.
- The disclosed concept, as described in greater detail herein in connection with various particular exemplary embodiments, provides methods and systems for effectively administering exogenous melatonin so as to meaningfully accelerate the onset of sleep. It should be noted that exogenous melatonin is administered to effect a timing function of sleep rather than a hypnotic effect; that is, exogenous melatonin is administered to influence when a person falls asleep but may not affect the total amount of time that a person sleeps. Research literature shows that responses to melatonin administered exogenously (i.e. ingested) are greatest when at times when endogenous levels (i.e. natural bodily production levels) are not normally present, that is, during the day. Conversely, the effect of taking melatonin during the time when it is already being produced by the body (i.e. during the night) is minimal. When taken in the late night/morning, melatonin causes phase delays (shifts to a later time) in the body's biological night as defined by the body's circadian rhythm, and when ingested in the afternoon or evening, exogenous melatonin causes phase advances (shifts to an earlier time) in the body's biological night as defined by the body's circadian rhythm.
- The conditions during which melatonin is administered appear to be very important and may dictate the effectiveness of any given dose, particularly with respect to acute changes in core body temperature (CBT) and sleepiness. Accordingly, the disclosed concept provides a system for optimizing the effectiveness of melatonin treatment by detecting hormone sensitivity through sleep architecture monitoring and personalizing dosing in relation to users' behaviors, needs and health conditions. As used herein, the terms “dose”, “dosage”, and “dosing” encompass both the quantity of melatonin to be taken and the timing of ingestion of the melatonin relative to a desired sleep event or time of day.
-
FIG. 1 is a schematic depiction of amelatonin optimization system 10 for maximizing melatonin effectiveness based on a user's needs, characteristics, and behavior, in accordance with an exemplary embodiment of the disclosed concept, andFIG. 2 is a schematic depiction of asystem 100 that is a more detailed variation of thesystem 10.FIG. 2 also depicts some of the decision making executed by the components ofsystems behavior detection module 15 is depicted as being separate from arecommendation engine 16 inFIG. 1 while being depicted as part of therecommendation engine 16 inFIG. 2 , and that either configuration can be used without departing from the scope of the disclosed concept. Thesystem systems - Referring to
FIGS. 1 and 2 , auser interface 11 allows the user to provide information about his or her age, gender, usual bed time, timing and dosage of caffeine and alcohol intake, health conditions (e.g. high blood pressure, insomnia, diabetes, beta-blocker intake, jet-lag), and desired sleep outcome(s) (i.e. sleep onset latency, sleep/wake time, sleep duration, etc.) to thesystem Such user interface 11 can, for example and without limitation, take the form of a mobile phone application or internet-based portal. An initialdose algorithm module 12 provides initial melatonin dose and timing recommendations for the user based on the age/gender/conditions/needs/desired sleep time data entered by the user into theuser interface 11. The initialdose algorithm module 12 can, for example and without limitation, be preprogrammed to utilize widely available data about recommended dosing based on problems recognized in the general population. Table 1 below provides a non-limiting example of widely available data providing a number of melatonin dosages that are recommended based on a user's specific conditions, needs, desired sleep outcomes, etc.: -
TABLE 1 Dosage of Melatonin Recommended for Specified Conditions User Condition Recommended Melatonin Dosage(s) for an Adult User has any one of a number of disorders 0.5 mg to 5 mg of melatonin taken daily before bedtime for up that affects when a person sleeps and when to 6 years, as has been used for blind people he/she is awake High dose of 10 mg melatonin taken 1 hour before bedtime for up to 9 weeks, as has been used for blind people 2 mg to 12 mg of melatonin taken at bedtime for up to four weeks User has trouble falling asleep at a 0.3 mg to 5 mg of melatonin daily for up to 9 months conventional bedtime (delayed sleep phase syndrome) User has sleep disturbance caused by 2.5 mg of melatonin daily for up to 4 weeks certain blood pressure medicine (beta Single doses of 5 mg blocker-induced insomnia) User has endometriosis 10 mg of melatonin daily for up to 8 weeks User has high blood pressure 2 mg to 3 mg of controlled-release melatonin daily for to 4 weeks User has insomnia 2 mg to 3 mg of melatonin daily before bedtime for up to 29 weeks Higher doses of up to 12 mg daily for shorter durations (up to 4 weeks) - A sleep
architecture detection module 13 includes a number of sensors and/or trackers and a number of algorithms for detecting the user's sleep architecture. Any type of sensor, tracker, or other device/method for collecting sleep architecture can be used without departing from the disclosed concept. Non-limiting examples of devices that can be used to detect sleep architecture include wrist worn devices, mattresses with sleep trackers, and user-entered sleep diaries. Aneffectiveness evaluation module 14 compares the user's desired sleep outcome (as indicated by the user's input to user interface 11) to the actual sleep outcome (as detected by the sleep architecture detection module 13), and a recommendation engine 16 (described in more detail below) then directs the user to either change the dosage/timing of the melatonin intake or execute a different intervention for changing a behavioral aspect based on the findings of theeffectiveness evaluation module 14. - A
behavior detection module 15 collects and processes sensor data and the user's self-reported information (input to the user interface 11) to detect information about the user's behavior, including but not limited to the user's exposure to light, physical activity, food intake, and stress level. In an exemplary embodiment of the disclosed concept, thebehavior detection module 15 includes, at a minimum: a wearable sensor for light exposure detection, a stress detector, an activity tracker, and an input from theuser interface 11 for self-reporting of food/alcohol/caffeine intake. The wearable sensor for light exposure detection can, for example and without limitation, detect and collect information about the duration, intensity and timing of both sun and artificial light to which a user is exposed throughout the day and up to the user's bed time. The stress detector can, for example and without limitation, be a wearable device that detects user physiological data such as heart rate variability and/or skin conductance. The assessment of stress level can be performed either by an on-device algorithm or by a third party via an application programming interface (API) call from the stress detector. The activity tracker can, for example and without limitation, be a wearable device that detects the number of minutes that the user is engaged in an aerobic activity, with aerobic activity being characterized by the user's heart rate level reaching between 55% and 85% of the user's maximum heart rate, the maximum heart rate (maxHR) being calculated using Equation (1) below: -
maxHR=207−0.7*(age of user) (1) - The user interface for self-reporting of food/alcohol/caffeine intake enables a user to report the amount and timing of his or her food, alcohol, and/or caffeine intake throughout the day.
- The
recommendation engine 16 comprises a melatonindose adjustment module 17 and abehavioral changes module 18 that evaluates the melatonin dose effectiveness and analyzes the detected user behavior along with the user's stated preferences to recommend melatonin dosing adjustments and/or behavioral changes for the user. More specifically, thedose adjustment module 17 determines the difference between the user's desired sleep onset latency and measured sleep onset latency (or any other chosen sleep metric), and recommends an intervention based on the effectiveness of any previous melatonin intervention, the current day's activities, and the prior night's sleep. If the recommended intervention is melatonin dosing and the previous melatonin dose already reached a predetermined maximum allowed level, then only behavioral changes will be recommended. Thebehavioral changes module 18 computes the difference between recommended behavior for the user and the user's measured behavior. If the behavior difference exceeds a pre-defined threshold, then an intervention is recommended. - Behavioral change recommendations are provided only for the actual behaviors that are being monitored. For example and without limitation, if the particular implementation of a
system 10 being used does not include a light sensor, then thebehavioral changes module 18 will not provide light exposure recommendations. A non-limiting list of behavioral change recommendations that can be provided by thebehavioral changes module 18 includes: directing the user to engage in an outdoor activity such as walking for at least 30 minutes a day, directing the user to turn off artificial lights at least two hours before the desired time of sleep onset, directing the user to engage in breathing exercises to assist in reducing the user's stress level, and directing the user to avoid caffeine intake after a specified time of day. - Referring once more to the
effectiveness module 14 ofsystems effectiveness module 14 can additionally predict non-intervention sleep onset (i.e. naturally occurring sleep onset) using a number of statistical or empirical techniques, and use the predicted non-intervention sleep onset as part of the evaluation of the effectiveness of any current intervention. The predicted non-intervention sleep onset can then be used by therecommendation engine 16 to determine a recommended intervention for the upcoming night (or other period of sleep). Referring toFIG. 3 , one non-limiting example of a technique that theeffectiveness module 14 can employ for predicting sleep onset is a two-process model of sleep alertness. The two-process model of sleep alertness uses time since awakening, time since falling asleep, and time of day to generate a sleep-dependent curve (Process S) and sleep-independent circadian curve (Process C). The Process S curve demonstrates that alertness is highest upon waking and decreases steadily throughout the day, reaching its lowest level at sleep onset (represented by the lowest value on the Process S curve). The Process S reverses at sleep onset and is called S′ until awakening. The S′ portion of the Process S curve shows that homeostatic sleep debt is relieved during sleep. - Still referring to
FIG. 3 , a predicted alertness level for the time of day is expressed as the arithmetic sum of the S and C curves (depicted as a dashed line S+C inFIG. 3 ). Sleep onset latency (SOL) for any given time of day can then be predicted using Equation (2) below: -
y=0.56*100.12x (2) - where x is the predicted alertness for a specified time of day (i.e. found by locating the S+C curve point corresponding to the time of day) and y is the sleep onset latency. It will be appreciated that the constants 0.56 and 0.12 in Equation (2) result from using known parameter estimation methods, wherein these constants were found by defining a best-fit relationship between observed alertness level and sleep onset latency of several research study test subjects. More specifically, for a lowest level of predicted alertness where x=1, it was found that the sleep latency y 0.5 minutes.
- The
effectiveness module 14 can include aSOL prediction module 140 incorporating a machine learning model 145 (theSOL prediction module 140 andmachine learning model 145 both being described in more detail with respect toFIGS. 4 and 5 ) to predict sleep onset latency n hours before the user's desired bedtime. The user's preferred bedtime can either be expressed by the user through theuser interface 11 or can be automatically detected from historical sleep architecture data collected by the sleeparchitecture detection module 13, by averaging bedtime detected over a week of use, and averaging bedtime separately over weekdays and weekends if different sleep routines are present in those two parts of the week. In a non-limiting exemplary embodiment of the disclosed concept, rather than predicting sleep onset latency using Equation (2) above, which is deemed applicable to the general population based on data compiled from several research subjects, themachine learning model 145 can be configured to implement a personalized SOL prediction tailored to a particular user of thesystem - Referring to
FIG. 4 , which shows a multi-modal inputSOL prediction module 140 that includes themachine learning model 145, andFIG. 5 , which shows the steps of amethod 200 for training themachine learning model 145 to predict sleep onset latency, themachine learning model 145 can be trained to make user-personalized SOL predictions by analyzing sleep architecture data collected by the sleeparchitecture detection module 13. The effect of training themachine learning model 145 to make personalized SOL predictions can be to find constants more personalized to the user than the constants 0.56 and 0.12 used in Equation (2), i.e. y=0.56*100.12x, and even to define a relationship other than the one defined in Equation (2) to predict sleep onset latency for the user. The accuracy of a personalized SOL prediction function that allows for multiple inputs (as the multi-modal inputSOL prediction module 140 does) can be maximized by minimizing the value of an error function defined in Equation (3) below: -
error(X)=Σi=0 K(measuredSOL(i)−predictedSOL(i)(X))2 (3) - wherein X represents all needed parameters (all such parameters being the parameters chosen as input to the multi-modal input SOL prediction module 140), and K is the number of days in the training phase. It will be appreciated that a number of known techniques for solving the minimization of an error function exist, for example and without limitation the gradient descent technique, and that any known optimization algorithm or other technique for minimizing the error function defined in Equation (3) can be used without departing from the scope of the disclosed concept.
- Still referring to
FIGS. 4 and 5 , to train themachine learning model 145 to predict sleep onset latency for a user, a new user is first directed atstep 201 of themethod 200 to use thesystem 10 orsystem 100 for a baseline period (e.g. one week) without taking any melatonin. Next, the user is directed atstep 202 to take varying doses of melatonin throughout the course of a subsequent testing period (e.g. one week), wherein the doses are defined as either minimum, maximum, or intermediate (e.g. the intermediate dose being defined as halfway between the maximum dose and minimum dose). Together, the baseline period and the testing period comprise a data collection period. It will be appreciated that the durations of the baseline period and the testing period can be longer or shorter than one week, and that the durations of the baseline period and the testing period can vary from one another without departing from the scope of the disclosed concept. The testing period or baseline period for the user can also be omitted entirely without departing from the disclosed concept such that themachine learning model 145 can be trained using comparable available data from dedicated research trials wherein sleep architecture data was collected for multiple research subjects who underwent a baseline period and a testing period; however, it will be appreciated that the SOL prediction made by themachine learning model 145 in that instance would not be personalized for the user of thesystem - In
FIG. 4 , theSOL prediction module 140 is depicted as including a two-process (2-P) SOL prediction module. The 2-P SOL prediction module uses an algorithm that takes the two processes of homeostatic sleep drive and circadian timing (i.e. the Process S curve and the Process C curve, respectively, shown inFIG. 3 ) into account in predicting sleep onset latency. However, it will be appreciated that the Unified Model of Performance, the SAFTE model, or any other biological model that takes into account homeostatic sleep drive and circadian timing can be used in place of the 2-P model in theSOL prediction module 140 without departing from the scope of the disclosed concept. Referring toFIG. 5 , a determination is made atstep 203 about whether a multi-modal SOL prediction will be sought instep 205, i.e. a SOL prediction that takes behavior into account in addition to homeostatic sleep drive and circadian timing. If a multi-modal SOL will be sought, then data collected by thebehavior detection module 15 about the user's behavior is provided to themachine learning model 145 atstep 204. If a multi-modal SOL prediction is not sought, theprocess 200 advances to step 205 fromstep 203. - At
step 205, themachine learning model 145 analyzes the baseline period data, the testing period data, and thebehavior detection module 15 data (if applicable) for each day of the data collection period and compares the data to the user's detected sleep architecture collected every day of the data collection period by the sleeparchitecture detection module 13 in order to determine patterns indicative of SOL. As previously stated with respect tosteps process 200, if a personalized SOL prediction is not sought, user baseline data and testing data may not be provided to themachine learning model 145 atstep 205, and research subject baseline data and testing data are instead provided so that themachine learning model 145 can compare the research subjects' baseline data and testing data to the research subjects' sleep architecture data in order to determine patterns indicative of SOL. - Once the
machine learning model 145 has been trained usingmethod 200 to recognize patterns and associations between sleep architecture data and baseline period data, testing period data, and behavior data (if applicable), themachine learning model 145 is capable of making a reliable SOL prediction based on newly provided data about the user's sleep architecture from the previous night (or other sleeping period), the most recent melatonin dose taken by the user, and the user's most recent behavior (if applicable). It will be appreciated that several techniques are available for building a machine learning model such as themachine learning model 145 used in theSOL prediction module 140, including but not limited to decision tree regressors, generalized linear models, and other regression modeling task solutions, and that any technique for building a machine learning model may be used to buildmachine learning model 145 without departing from the scope of the disclosed concept. - In the claims, any reference signs placed between parentheses shall not be construed as limiting the claim. The word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim. In a device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements. In any device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
- Although the invention has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover modifications and equivalent arrangements that are within the spirit and scope of the appended claims. For example, it is to be understood that the present invention contemplates that, to the extent possible, one or more features of any embodiment can be combined with one or more features of any other embodiment.
Claims (15)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/132,424 US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
PCT/EP2021/070193 WO2022018049A1 (en) | 2020-07-20 | 2021-07-20 | Optimized effectiveness based sleep aid management |
EP21754706.6A EP4182938A1 (en) | 2020-07-20 | 2021-07-20 | Optimized effectiveness based sleep aid management |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054197P | 2020-07-20 | 2020-07-20 | |
US17/132,424 US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220020286A1 true US20220020286A1 (en) | 2022-01-20 |
Family
ID=77265057
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
US17/132,424 Pending US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
US17/363,714 Pending US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
US17/363,242 Pending US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
US17/363,714 Pending US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
US17/363,242 Pending US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
Country Status (5)
Country | Link |
---|---|
US (8) | US11837106B2 (en) |
EP (8) | EP4182948A1 (en) |
JP (2) | JP2023534133A (en) |
CN (5) | CN116171478A (en) |
WO (8) | WO2022017893A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022328131A1 (en) * | 2021-08-09 | 2024-02-15 | Y-Prime, LLC | Risk assessment and intervention platform architecture for predicting and reducing negative outcomes in clinical trials |
WO2024107108A1 (en) * | 2022-11-14 | 2024-05-23 | National University Of Singapore | Computer implemented methods of generating dose recommendations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150282768A1 (en) * | 2012-09-29 | 2015-10-08 | Aliphcom | Physiological signal determination of bioimpedance signals |
US20170100066A1 (en) * | 2015-10-08 | 2017-04-13 | International Business Machines Corporation | Identifying Stress Levels Associated with Context Switches |
US20200350073A1 (en) * | 2019-05-02 | 2020-11-05 | Closed Loop Medicine Ltd. | Methods and Systems for Providing Personalised Medicine to a Patient |
US20220401689A1 (en) * | 2019-09-24 | 2022-12-22 | Delos Living Llc | Systems and methods for enhancing sleep patterns |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6349724B1 (en) * | 2000-07-05 | 2002-02-26 | Compumedics Sleep Pty. Ltd. | Dual-pressure blower for positive air pressure device |
US20050080348A1 (en) | 2003-09-18 | 2005-04-14 | Stahmann Jeffrey E. | Medical event logbook system and method |
US7468040B2 (en) * | 2003-09-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Methods and systems for implantably monitoring external breathing therapy |
US7680537B2 (en) | 2003-08-18 | 2010-03-16 | Cardiac Pacemakers, Inc. | Therapy triggered by prediction of disordered breathing |
EP1670547B1 (en) * | 2003-08-18 | 2008-11-12 | Cardiac Pacemakers, Inc. | Patient monitoring system |
US7591265B2 (en) * | 2003-09-18 | 2009-09-22 | Cardiac Pacemakers, Inc. | Coordinated use of respiratory and cardiac therapies for sleep disordered breathing |
SE0401208D0 (en) * | 2004-05-10 | 2004-05-10 | Breas Medical Ab | Multilevel fan |
JP5425793B2 (en) * | 2007-10-12 | 2014-02-26 | ペイシェンツライクミー, インコーポレイテッド | Personal management and comparison of medical conditions and outcomes based on patient community profiles |
WO2010080405A1 (en) * | 2008-12-19 | 2010-07-15 | The Board Of Trustees Of The University Of Illinois | Detection and prediction of physiological events in people with sleep disordered breathing using a lamstar neural network |
US8979730B2 (en) * | 2009-06-04 | 2015-03-17 | Koninklijke Philips N.V. | Method and system for providing behavioural therapy for insomnia |
US8684006B2 (en) * | 2010-03-26 | 2014-04-01 | Advanced Brain Monitoring, Inc. | Systems and methods for optimizing oral appliance therapy for the treatment of sleep apnea |
WO2012071354A2 (en) * | 2010-11-23 | 2012-05-31 | Sanitas, Inc. | Disease management system using personalized education, patient support community and telemonitoring |
US11712557B2 (en) * | 2013-05-30 | 2023-08-01 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
JP6698521B2 (en) * | 2013-07-08 | 2020-05-27 | レスメッド センサー テクノロジーズ リミテッド | Sleep management method and system |
NZ630770A (en) * | 2013-10-09 | 2016-03-31 | Resmed Sensor Technologies Ltd | Fatigue monitoring and management system |
US20190076031A1 (en) * | 2013-12-12 | 2019-03-14 | Alivecor, Inc. | Continuous monitoring of a user's health with a mobile device |
US11437125B2 (en) * | 2014-06-13 | 2022-09-06 | University Hospitals Cleveland Medical Center | Artificial-intelligence-based facilitation of healthcare delivery |
US9241079B1 (en) * | 2014-06-27 | 2016-01-19 | Sap Se | Mobile application usage monitor |
US10278638B2 (en) * | 2014-07-21 | 2019-05-07 | Withings | System and method to monitor and assist individual's sleep |
US20160106344A1 (en) * | 2014-10-14 | 2016-04-21 | Milad Nazari | Methods and systems for detecting movement disorder |
US9889271B2 (en) * | 2015-01-05 | 2018-02-13 | Inteliclinic Inc. | System, apparatus and method for treating sleep disorder symptoms |
CA3081166A1 (en) * | 2015-01-06 | 2016-07-14 | David Burton | Mobile wearable monitoring systems |
US10690763B2 (en) * | 2015-04-20 | 2020-06-23 | Resmed Sensor Technologies Limited | Detection and identification of a human from characteristic signals |
JP6767394B2 (en) * | 2015-05-29 | 2020-10-14 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Devices to increase patient compliance with treatment for upper respiratory tract disease, how the devices operate, and computer programs |
US10582890B2 (en) * | 2015-08-28 | 2020-03-10 | Awarables Inc. | Visualizing, scoring, recording, and analyzing sleep data and hypnograms |
WO2018129351A1 (en) * | 2017-01-05 | 2018-07-12 | Shriram Raghunathan | Restless leg syndrome or overactive nerve treatment |
US20190000349A1 (en) * | 2017-06-28 | 2019-01-03 | Incyphae Inc. | Diagnosis tailoring of health and disease |
US11363984B2 (en) * | 2017-09-12 | 2022-06-21 | Snooze, Inc. | Method and system for diagnosis and prediction of treatment effectiveness for sleep apnea |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
IL255255A0 (en) * | 2017-10-25 | 2017-12-31 | Optimata Ltd | System and method for prediction of medical treatment effect |
WO2019084448A1 (en) * | 2017-10-26 | 2019-05-02 | Radial Medical, Inc. | Adaptive compression therapy systems and methods |
US11638795B2 (en) * | 2018-06-29 | 2023-05-02 | Koninklijke Philips N.V. | System and method for providing enhanced PAP metrics |
US11367519B1 (en) * | 2018-07-19 | 2022-06-21 | Great Lakes Neurotechnologies Inc. | Systems and methods for precision or personal pharmaceutical dosing |
CA3152384A1 (en) | 2018-09-06 | 2020-03-12 | Ian Cooke | Method of treating a sleep breathing disorder |
US11783949B2 (en) * | 2018-11-30 | 2023-10-10 | Ariel Precision Medicine, Inc. | Methods and systems for severity calculator |
CL2019000057A1 (en) | 2019-01-08 | 2019-04-12 | Sleepmed Spa | Method and system for predicting risk index in conditions of chronic intermittent hypobaric hypoxia by recording physiological parameters and anthropometric variables in real time. |
CN114072827A (en) * | 2019-03-15 | 2022-02-18 | 3M创新有限公司 | Personalized medicine using causal models |
US20210007659A1 (en) * | 2019-06-28 | 2021-01-14 | Teleplus Healthcare LLC | System and method for sleep disorders: screening, testing and management |
JP2022542580A (en) * | 2019-07-25 | 2022-10-05 | インスパイア・メディカル・システムズ・インコーポレイテッド | Sleep detection for sleep-disordered breathing (SDB) care |
EP4038629A1 (en) * | 2019-09-30 | 2022-08-10 | F. Hoffmann-La Roche AG | Prediction of disease status |
US20220406420A1 (en) * | 2019-09-30 | 2022-12-22 | Resmed Sensor Technologies Limited | Systems and methods for predicting adoption of a therapy |
US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
KR20220149552A (en) * | 2020-03-02 | 2022-11-08 | 슬립 넘버 코포레이션 | Bed with user context sensing feature |
CN113520340B (en) * | 2020-04-15 | 2022-11-08 | 华为技术有限公司 | Sleep report generation method, device, terminal and storage medium |
WO2021220247A1 (en) * | 2020-04-30 | 2021-11-04 | Resmed Sensor Technologies Limited | Systems and methods for promoting a sleep stage of a user |
-
2020
- 2020-11-30 US US17/106,827 patent/US11837106B2/en active Active
- 2020-12-23 US US17/132,424 patent/US20220020286A1/en active Pending
- 2020-12-23 US US17/132,503 patent/US20220020492A1/en active Pending
- 2020-12-30 US US17/138,242 patent/US20220016369A1/en active Pending
- 2020-12-30 US US17/138,272 patent/US20220016371A1/en active Pending
-
2021
- 2021-06-30 US US17/363,714 patent/US20220020461A1/en active Pending
- 2021-06-30 US US17/363,353 patent/US20220020468A1/en active Pending
- 2021-06-30 US US17/363,242 patent/US20220020463A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069691 patent/WO2022017893A1/en unknown
- 2021-07-15 EP EP21751506.3A patent/EP4182948A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069677 patent/WO2022017891A1/en unknown
- 2021-07-15 CN CN202180060534.1A patent/CN116171478A/en active Pending
- 2021-07-15 JP JP2022578701A patent/JP2023534133A/en active Pending
- 2021-07-15 EP EP21751507.1A patent/EP4182939A1/en active Pending
- 2021-07-16 WO PCT/EP2021/070048 patent/WO2022017989A1/en unknown
- 2021-07-16 EP EP21751771.3A patent/EP4182950A1/en active Pending
- 2021-07-16 CN CN202180059498.7A patent/CN116210057A/en active Pending
- 2021-07-16 WO PCT/EP2021/070052 patent/WO2022017991A1/en unknown
- 2021-07-16 EP EP21751773.9A patent/EP4182951A1/en active Pending
- 2021-07-16 JP JP2023503459A patent/JP2023537223A/en active Pending
- 2021-07-17 CN CN202180060076.1A patent/CN116171477A/en active Pending
- 2021-07-17 EP EP21751774.7A patent/EP4182952A1/en active Pending
- 2021-07-17 WO PCT/EP2021/070062 patent/WO2022017993A1/en unknown
- 2021-07-17 WO PCT/EP2021/070063 patent/WO2022017994A1/en unknown
- 2021-07-17 EP EP21751995.8A patent/EP4182953A1/en active Pending
- 2021-07-17 CN CN202180060209.5A patent/CN116134548A/en active Pending
- 2021-07-20 WO PCT/EP2021/070192 patent/WO2022018048A1/en unknown
- 2021-07-20 EP EP21754705.8A patent/EP4182954A1/en active Pending
- 2021-07-20 WO PCT/EP2021/070193 patent/WO2022018049A1/en unknown
- 2021-07-20 EP EP21754706.6A patent/EP4182938A1/en active Pending
- 2021-07-20 CN CN202180059048.8A patent/CN116134547A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150282768A1 (en) * | 2012-09-29 | 2015-10-08 | Aliphcom | Physiological signal determination of bioimpedance signals |
US20170100066A1 (en) * | 2015-10-08 | 2017-04-13 | International Business Machines Corporation | Identifying Stress Levels Associated with Context Switches |
US20200350073A1 (en) * | 2019-05-02 | 2020-11-05 | Closed Loop Medicine Ltd. | Methods and Systems for Providing Personalised Medicine to a Patient |
US20220401689A1 (en) * | 2019-09-24 | 2022-12-22 | Delos Living Llc | Systems and methods for enhancing sleep patterns |
Also Published As
Publication number | Publication date |
---|---|
WO2022017994A1 (en) | 2022-01-27 |
JP2023534133A (en) | 2023-08-08 |
CN116134548A (en) | 2023-05-16 |
WO2022018049A1 (en) | 2022-01-27 |
WO2022018048A1 (en) | 2022-01-27 |
US20220020461A1 (en) | 2022-01-20 |
EP4182938A1 (en) | 2023-05-24 |
EP4182939A1 (en) | 2023-05-24 |
WO2022017891A1 (en) | 2022-01-27 |
US20220020501A1 (en) | 2022-01-20 |
WO2022017991A1 (en) | 2022-01-27 |
US20220016371A1 (en) | 2022-01-20 |
CN116171477A (en) | 2023-05-26 |
EP4182952A1 (en) | 2023-05-24 |
US20220020492A1 (en) | 2022-01-20 |
WO2022017993A1 (en) | 2022-01-27 |
EP4182951A1 (en) | 2023-05-24 |
WO2022017989A1 (en) | 2022-01-27 |
CN116171478A (en) | 2023-05-26 |
EP4182953A1 (en) | 2023-05-24 |
WO2022017893A1 (en) | 2022-01-27 |
EP4182948A1 (en) | 2023-05-24 |
EP4182950A1 (en) | 2023-05-24 |
US20220020468A1 (en) | 2022-01-20 |
US11837106B2 (en) | 2023-12-05 |
EP4182954A1 (en) | 2023-05-24 |
CN116134547A (en) | 2023-05-16 |
US20220020463A1 (en) | 2022-01-20 |
US20220016369A1 (en) | 2022-01-20 |
CN116210057A (en) | 2023-06-02 |
JP2023537223A (en) | 2023-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martinez-Nicolas et al. | Crosstalk between environmental light and internal time in humans | |
US20220020286A1 (en) | Optimized effectiveness based sleep aid management | |
Swaminathan et al. | Are individual differences in sleep and circadian timing amplified by use of artificial light sources? | |
US20170132946A1 (en) | Method and system for providing feedback to user for improving performance level management thereof | |
US20220079512A1 (en) | System and method for determining a level of alertness | |
JP6709154B2 (en) | Apparatus, method, system for calculating the current circadian rhythm of a human, and computer program for performing the method | |
Ostrin et al. | Sleep in myopic and non-myopic children | |
US11793454B2 (en) | Method and system for providing feedback to user for improving performance level management thereof | |
WO2024055931A1 (en) | Exercise recommendation method and apparatus, sleep recommendation method and apparatus, electronic device, and storage medium | |
Yetish et al. | Sleep variability and nighttime activity among Tsimane forager‐horticulturalists | |
JPH053920A (en) | Biorhythm adjusting device | |
Martin et al. | Timely use of in-car dim blue light and blue blockers in the morning does not improve circadian adaptation of fast rotating shift workers | |
Lee et al. | Continuous 24-hour ocular dimensional profile recording in medically treated normal-tension glaucoma | |
Evans et al. | CBT-I for patients with phase disorders or insomnia with circadian misalignment | |
CN116134534A (en) | Sleep assistance management based on optimized availability | |
US20230157631A1 (en) | Systems and methods for monitoring and control of sleep patterns | |
Canazei et al. | Actigraphy for assessing light effects on sleep and circadian activity rhythm in Alzheimer's dementia: a narrative review | |
Dooley et al. | Method for Activity Sleep Harmonization (MASH): a novel method for harmonizing data from two wearable devices to estimate 24-h sleep–wake cycles | |
US20170061011A1 (en) | Server and data search method | |
Charbonnier et al. | Toward a portable blood pressure recorder device equipped with an accelerometer | |
Babilon et al. | Study protocol for measuring the impact of (quasi-) monochromatic light on post-awakening cortisol secretion under controlled laboratory conditions | |
US20240108282A1 (en) | System and method for providing sleep consolidation therapy | |
Krogh et al. | Randomized controlled light intervention in an occupational setting and the effects on stress and work performance | |
KR20230104032A (en) | Method and system for biorhythm improvement | |
Arif et al. | Does Misalignment Between Social and Biological Clocks Induce Severe Atopic Dermatitis? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KONINKLIJKE PHILIPS N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARGARITO, JENNY;KRON, SARA;SHELLY, BENJAMIN IRWIN;SIGNING DATES FROM 20201222 TO 20201231;REEL/FRAME:054959/0269 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |